Avalo Therapeutics (NASDAQ: AVTX) CFO details Form 4 stock trade filing

Rhea-AI Filing Summary

Avalo Therapeutics, Inc. chief financial officer Christopher Sullivan reported a change in his ownership of Avalo common stock. On 12/10/2025, 155 shares of common stock were disposed of at $4.1 per share, leaving him with beneficial ownership of 17,338 shares.

The beneficially owned amount includes 417 additional shares acquired pursuant to Avalo Therapeutics, Inc.'s Employee Stock Purchase Plan as a part of this reporting transaction. The report is a Form 4 filed by one reporting person in his capacity as an officer (chief financial officer).

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sullivan Christopher Ryan

(Last) (First) (Middle)

C/O AVALO THERAPEUTICS, INC.

1500 LIBERTY RIDGE DRIVE, SUITE 321

(Street)

WAYNE PA 19087

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Avalo Therapeutics, Inc. [ AVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/10/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/10/2025		F		155	D	$4.1	17,338(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Includes 417 additional shares acquired pursuant to the Issuer's Employee Stock Purchase Plan as a part of this reporting transaction.

	/s/ Christopher Sullivan	12/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider stock transaction did Avalo Therapeutics (AVTX) report for its CFO?

Avalo Therapeutics reported that chief financial officer Christopher Sullivan disposed of 155 shares of Avalo common stock on 12/10/2025 at a price of $4.1 per share.

How many Avalo Therapeutics (AVTX) shares does the CFO own after this Form 4?

Following the reported transaction, Avalo Therapeutics CFO Christopher Sullivan beneficially owns 17,338 shares of Avalo common stock.

Does the Avalo Therapeutics CFO’s share count include Employee Stock Purchase Plan shares?

Yes. The reported 17,338 shares beneficially owned by the CFO include 417 additional shares acquired pursuant to Avalo Therapeutics, Inc.'s Employee Stock Purchase Plan as part of this transaction.

What is Christopher Sullivan’s role and relationship to Avalo Therapeutics (AVTX)?

Christopher Sullivan is an officer of Avalo Therapeutics, Inc., serving as the company’s chief financial officer, and he filed this Form 4 as a single reporting person.

What type of security is involved in this Avalo Therapeutics (AVTX) Form 4?

The Form 4 relates to transactions in Avalo Therapeutics, Inc. common stock, as shown in the non-derivative securities table.